专利检索 cpc:"C07D209/30" 第 1 页

1.

发明公开
ESTROGEN RECEPTOR-MODULATING COMPOUNDS 审中-公开

公开(公告)号：US20240308986A1

公开(公告)日：2024-09-19

申请号：US18661960

申请日：2024-05-13

申请人： RADIUS PHARMACEUTICALS, INC.

发明人： Chris MILLER

IPC分类号： C07D403/10 , A61P35/04 , C07D209/30 , C07D333/64 , C07D409/12 , C07D487/04 , C07D495/04

CPC分类号： C07D403/10 , A61P35/04 , C07D209/30 , C07D333/64 , C07D409/12 , C07D487/04 , C07D495/04

摘要： Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

2.

发明授权
Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides 有权

公开(公告)号：US12071404B2

公开(公告)日：2024-08-27

申请号：US17506331

申请日：2021-10-20

申请人： UCB Pharma GmbH

发明人： Christa E. Mueller , Cécile Pegurier , Michael Louis Robert Deligny , Ali El-Tayeb , Joerg Hockemeyer , Marie Ledecq , Joël Mercier , Laurent Provins , Nader M. Boshta , Sanjay Bhattarai , Vigneshwaran Namasivayam , Mario Funke , Lukas Schwach , Sabrina Gollos , Daniel Von Laufenberg , Anaïs Barré

IPC分类号： C07D209/30 , C07D307/82 , C07D333/62 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D421/12 , C07D487/04 , C07D491/056

CPC分类号： C07D209/30 , C07D307/82 , C07D333/62 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D421/12 , C07D487/04 , C07D491/056

摘要： Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

3.

发明授权
Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders 有权

公开(公告)号：US12065459B2

公开(公告)日：2024-08-20

申请号：US16672114

申请日：2019-11-01

申请人： Achillion Pharmaceuticals, Inc.

发明人： Jason Allan Wiles , Venkat Rao Gadhachanda , Qiuping Wang , Godwin Pais , Akihiro Hashimoto , Dawei Chen , Xiangzhu Wang , Atul Agarwal , Milind Deshpande , Avinash S. Phadke

IPC分类号： C07F9/572 , A61K9/00 , A61K31/404 , A61K31/4045 , A61K31/407 , A61K31/4162 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/675 , A61K31/683 , C07B59/00 , C07D209/12 , C07D209/14 , C07D209/30 , C07D209/40 , C07D209/42 , C07D209/44 , C07D209/88 , C07D401/14 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/14 , C07D491/113 , C07D495/04 , C07D513/04 , C07F5/02 , C07F7/08 , C07F9/6558 , C07F9/6561

CPC分类号： C07F9/5728 , A61K9/0014 , A61K9/0019 , A61K9/0048 , A61K9/0053 , A61K31/404 , A61K31/4045 , A61K31/407 , A61K31/4162 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/675 , A61K31/683 , C07B59/002 , C07D209/12 , C07D209/14 , C07D209/30 , C07D209/40 , C07D209/42 , C07D209/44 , C07D209/88 , C07D401/14 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/14 , C07D491/113 , C07D495/04 , C07D513/04 , C07F5/025 , C07F5/027 , C07F7/0812 , C07F9/65583 , C07F9/6561 , C07F9/65616 , C07B2200/05

摘要： Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

4.

发明授权
Activator of TREK (TWIK RElated K 有权

公开(公告)号：US11851428B2

公开(公告)日：2023-12-26

申请号：US17328814

申请日：2021-05-24

申请人： ONO PHARMACEUTICAL CO., LTD. , VANDERBILT UNIVERSITY

发明人： Craig W. Lindsley , Joshua M. Wieting , Kevin M. Mcgowan , Jerod S. Denton , Kentaro Yashiro , Haruto Kurata , Yoko Sekioka , Takahiro Mori , Yuzo Iwaki

IPC分类号： C07D213/36 , C07D231/12 , C07D249/08 , C07D401/04 , A61K31/454 , C07D471/04 , C07C255/57 , C07C317/28 , C07D209/30 , C07D213/89 , C07D231/56 , C07D235/16 , C07D237/24 , C07D239/47 , C07D249/18 , C07D257/04 , C07D265/36 , C07D271/10 , C07D285/14 , C07D295/04 , C07D513/04

CPC分类号： C07D471/04 , C07C255/57 , C07C317/28 , C07D209/30 , C07D213/89 , C07D231/56 , C07D235/16 , C07D237/24 , C07D239/47 , C07D249/08 , C07D249/18 , C07D257/04 , C07D265/36 , C07D271/10 , C07D285/14 , C07D295/04 , C07D401/04 , C07D513/04

摘要： Disclosed is a compound of formula (I):

wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

5.

发明公开
SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE 审中-公开

公开(公告)号：US20230285598A1

公开(公告)日：2023-09-14

申请号：US17416180

申请日：2019-12-20

申请人： Takeda Pharmaceutical Company Limited

发明人： Laura EDGINGTON-MITCHELL , Simon MOUNTFORD , Bethany M. ANDERSON , Monika SZABO , Luigi AURELIO , Philip THOMPSON

IPC分类号： A61K49/00 , C07D209/30 , G01N33/58

CPC分类号： A61K49/0052 , C07D209/30 , G01N33/582 , G01N2333/96466

摘要： The present invention relates to compounds of formula I bearing a sulfoxoniumylide moiety as warhead, or salts thereof. Such compounds can be used as activity-based probes for cysteine proteases such as cathepsin X, in methods of detecting cysteine protease activity and in related diagnostic or therapeutic methods.

6.

发明申请
Method for the Preparation of H-Arg(MIS)-OH 审中-公开

公开(公告)号：US20190241517A1

公开(公告)日：2019-08-08

申请号：US15569221

申请日：2016-10-09

申请人： POLYPEPTIDE LABORATORIES HOLDING (PPL) AB

发明人： Deyong Tan , Joanna Dai , Matthieu Giraud , Fernando Albericio Palomera

IPC分类号： C07D209/30

CPC分类号： C07D209/30

摘要： The invention discloses a method for the preparation of N-omega-(1,2-dimethylindole-3-sulfonyl)-L-arginine and its derivatives using L-ornithine.

7.

发明申请
Pharmaceutical Compound 审中-公开

公开(公告)号：US20180258075A1

公开(公告)日：2018-09-13

申请号：US15760697

申请日：2016-09-12

申请人： Merck Sharp & Dohme Corp. , IOmet Pharma Ltd.

发明人： Phillip M. Cowley , Yongxin Han

IPC分类号： C07D403/12 , A61K31/4155 , A61K45/06

CPC分类号： C07D403/12 , A61K31/404 , A61K31/4155 , C07D209/30 , A61K2300/00

摘要： Provided is a compound having formula (I): wherein R2 is selected from —C1, —Br and —CN; R1 and R4 are independently selected from H and —F; R631, R632, R641 and R642 are independently selected from —H, —F and substituted or unsubstituted C1-C3 alkyl groups; and R651 and R652 are independently selected from H and substituted or unsubstituted C1-C3 alkyl groups and substituted or unsubstituted phenyl groups; and wherein at least one of R631, R632, R641, R642 and R652 is not —H, or wherein when all of R631, R632, R641, R642 and R652 are —H, R651 is not Me or Et.